Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

67th Annual Scientific Sessions of the American College of Cardiology

10-12 March 2018, Orlando, Florida, USA

ODYSSEY Outcomes: alirocumab reduces cardiovascular events and death after acute coronary syndrome

ODYSSEY Outcomes: alirocumab reduces cardiovascular events and death after acute coronary syndrome

Top-line results presented at the 67th Scientific Sessions of the American College of Cardiology, Orlando, Florida provide definitive evidence for targeting PCSK9 inhibition to patients at highest risk with persistently elevated LDL cholesterol levels despite intensive statin therapy. Although further data are needed, this is…

read more »
ODYSSEY OUTCOMES to report at ACC.2018

ODYSSEY OUTCOMES to report at ACC.2018

The second completed cardiovascular outcomes study with a PCSK9 inhibitor will be up first at the first latebreaker session at the American College of Cardiology Scientific Sessions this March. ODYSSEY OUTCOMES with alirocumab follows reporting of FOURIER with evolocumab and the terminated SPIRE studies with…

read more »